{"text_format":"1","workbook":"xlsx","n_sheets":1,"sheets":["CF_E"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":0,"defined_names":0,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900"}

{"sheet":"CF_E","index":0,"n_rows":54,"n_cols":6,"rows_kept":54,"cut":false,"hidden":false,"merged":[[2,1,2,2]]}
[]
[null,"Consolidated statement of cash flows (IFRS)"]
[null,"from 1 October 2018 to 30 September 2019"]
[null,null,"2018/19\n1 Oct 18 to 30 Sep 19","2017/18\n1 Oct 17 to 30 Sep 18"]
[null,null,"€ k","€ k"]
[null,"Cash flows from operating activities:"]
[null,"Consolidated profit",160579,{"$f":"126310-233+153","v":126230}]
[null,"Adjustments to reconcile consolidated profit to net cash \nprovided by / (used in) operating activities"]
[null,"Income taxes",69279,{"$f":"53106-153","v":52953}]
[null,"Interest income / expenses",6409,1680]
[null,"       Results from other investments ",-34,-34]
[null,"Result from disposal of legal entity / hydrophilic IOL business Aaren Scientific Inc.",0,-2527]
[null,"Depreciation and amortisation",48370,31282]
[null,"Gains / losses on disposal of fixed assets ",719,2454]
[null,"       Dividends received",34,34]
[null,"Interest received",1774,{"$f":"933+13","v":946}]
[null,"Interest paid",-1903,{"$f":"-1952+13-1","v":-1940}]
[null,"Refunded income taxes",6003,2583]
[null,"Income taxes paid",-71073,-50947]
[null,"Changes in working capital:"]
[null,"Trade receivables",-20607,{"$f":"535+51-699","v":-113}]
[null,"Inventories",-11349,-11758]
[null,"Other assets",6542,{"$f":"5816+699","v":6515}]
[null,"Trade payables",14695,{"$f":"862-51+109+1","v":921}]
[null,"Provisions and financial liabilities",14564,{"$f":"22419-0-26","v":22393}]
[null,"Other liabilities",-4368,6535]
[null,"Total adjustments",59055,{"$f":"SUM(D9:D26)","v":60977}]
[null,"Net cash provided by / (used in) operating activities",219634,{"$f":"+D7+D27","v":187207}]
[null,"Cash flows from investing activities::"]
[null,"Investment in property, plant and equipment",-20348,{"$f":"-16426-109","v":-16535}]
[null,"Investment in other intangible assets",-26363,-18221]
[null,"Proceeds from fixed assets",887,467]
[null,"Proceeds from sale of investments",149,0]
[null,"Payments for other loans",-177,0]
[null,"Investment/ divestment in securities",-4857,3220]
[null,"Purchase of shares in affiliated non-consolidated companies",1196,0]
[null,"Purchase of shares in affiliated consolidated companies, net of cash acquired",-96333,-353]
[null,"Proceeds from disposal of legal entity / hydrophilic IOL business Aaren Scientific Inc.",0,2548,null,"incl sale of subsidiary Hexavision"]
[null,"Net cash provided by / (used in) investing activities",{"$f":"SUM(C30:C38)","v":-145846},{"$f":"SUM(D30:D38)","v":-28874}]
[null,"Cash flows from financing activities:"]
[null,"Proceeds from / (repayment of) current liabilities to banks",-103,-102]
[null,"Proceeds from / (repayment of) non-current liabilities to banks",0,-482]
[null,"(Increase) / decrease in treasury receivables",11619,-33663]
[null,"Increase / (decrease) in treasury payables",-1672,-65315]
[null,"Increase / (decrease) in liabilities due to finance lease",-13663,-2932]
[null,"      Dividend payments to shareholders of Carl Zeiss Meditec AG",-49192,-49192]
[null,"Dividend payments to non-controlling interests",-5626,-5551]
[null,"Net cash provided by / (used in) financing activities",{"$f":"SUM(C41:C47)","v":-58637},{"$f":"SUM(D41:D47)","v":-157237}]
[null,"Effect of exchange rate fluctuation on cash and cash equivalents",810,-345]
[null,"Effect of changes in scope of consolidation on cash and cash equivalents",0,{"$f":"1680+322","v":2002}]
[null,"Net increase / (decrease)  in cash and cash equivalents",{"$f":"+C28+C39+C48+C49+C50","v":15961},{"$f":"+D28+D39+D48+D49+D50","v":2753}]
[null,"Cash and cash equivalents, beginning of reporting period",6678,3925]
[null,"Cash and cash equivalents, end of reporting period",{"$f":"+C51+C52","v":22639},{"$f":"+D51+D52","v":6678}]
[null,"The following notes are an integral part of the audited consolidated financial statements."]